Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Expands Business In Turkey, India

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo is expanding operations in India and Turkey as it builds its sales networks. The Japanese drug maker said the first expansion is in Turkey with its Daiichi Sankyo Ilac Ticaret wholly owned subsidiary. The Turkey unit already is operating, with 20 medical representatives to market Daiichi's Evista (raloxifene hydrochloride) osteoporosis treatment. The India entry is expected to begin in June with Daiichi's promotion agreement with GlaxoSmithKline of the U.K. (Click here for more - may require a subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts